Most Read Articles
Roshini Claire Anthony, 13 Aug 2018

A genotype-guided approach to warfarin dosing may result in fewer dose adjustments in Asian patients, according to a study from Singapore.

Rachel Soon, 6 days ago

At the recent Malaysian Community Pharmacy Business Forum (MyCPBF), a discussion forum was held on the subject of “Transcending Primary Healthcare Services: The Future of Specialized Pharmacy Services and Pharmacy Specialization”.

19 Jul 2018
Nonsteroidal anti-inflammatory drugs (NSAIDs) appear to increase the risk of major bleeding, stroke or systemic embolism, and hospitalization among patients with atrial fibrillation (AF), suggest the results of the RE-LY* trial. Moreover, there is no difference in the safety and efficacy of dabigatran etexilate (DE) 150 and 110 mg twice daily relative to warfarin.
09 Dec 2017
Hydrochlorothiazide (HCTZ) appears to significantly increase the risks of nonmelanoma skin cancer (NMSC), particularly squamous cell carcinoma (SCC), a recent study has shown.

Cabergoline inadequate for preventing weight regain

04 Dec 2018

The dopamine agonist cabergoline does not provide clear benefits for maintaining weight loss in obese individuals who have shed >5 percent of body weight during a very low-calorie diet, according to the results of the 2-year Prevention of Weight Regain (POWER) study.

POWER randomized 221 obese patients (mean age 48 years; 94 percent female; mean body mass index [BMI], 37.4 kg/m2), who lost weight through an 800-kcal/day commercial meal replacement programme, to receive either cabergoline 0.5 mg (n=110) or placebo (n=111) taken orally once weekly.

At 24 months following randomization, the primary outcome measure of mean body weight did not significantly differ between the two treatment arms (mean difference, 0.6 kg; 95 percent CI, −1.5 to 2.6; p=0.58).

The mean baseline body weight of the cohort was 101.8 kg, with the 800-kcal/day diet producing a mean 7.1-kg reduction in weight. The mean weight regain at 24 months was 5.1 kg. BMI, percent weight loss, waist circumference, resting energy expenditure, blood pressure or metabolic parameters at 24 months were comparable between the cabergoline and placebo arms.

The findings do not support a major role for dopamine-mediated addiction-like mechanisms in curbing weight regain following acute weight loss, researchers said. The data also challenge the hypothesis that reduced central dopamine activity is a significant contributor to weight gain and obesity.

Dopamine is implicated in motivation and reward-driven eating, which strongly contributes to overeating, weight gain and obesity. The compound also factors in the regulation of inhibitory control, emotional status and other known biopsychosocial determinants of obesity. [Biol Psychiatry 2013;73:811-818; Annu Rev Nutr 2017;37:183-205]

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 13 Aug 2018

A genotype-guided approach to warfarin dosing may result in fewer dose adjustments in Asian patients, according to a study from Singapore.

Rachel Soon, 6 days ago

At the recent Malaysian Community Pharmacy Business Forum (MyCPBF), a discussion forum was held on the subject of “Transcending Primary Healthcare Services: The Future of Specialized Pharmacy Services and Pharmacy Specialization”.

19 Jul 2018
Nonsteroidal anti-inflammatory drugs (NSAIDs) appear to increase the risk of major bleeding, stroke or systemic embolism, and hospitalization among patients with atrial fibrillation (AF), suggest the results of the RE-LY* trial. Moreover, there is no difference in the safety and efficacy of dabigatran etexilate (DE) 150 and 110 mg twice daily relative to warfarin.
09 Dec 2017
Hydrochlorothiazide (HCTZ) appears to significantly increase the risks of nonmelanoma skin cancer (NMSC), particularly squamous cell carcinoma (SCC), a recent study has shown.